- Home
- APAD vs VYGR Comparison
APAD vs VYGR Comparison
Compare APAD & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APAD | VYGR |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.8M | 222.4M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | APAD | VYGR |
|---|---|---|
| Price | $10.10 | $3.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 74.7K | ★ 631.7K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.77 |
| P/E Ratio | $60.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $2.65 |
| 52 Week High | $10.21 | $5.55 |
Technical Indicators
Market Signals| Indicator | APAD | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 35.39 |
| Support Level | $10.08 | $3.36 |
| Resistance Level | $10.11 | $3.91 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 88.89 | 13.75 |
Price Performance
Historical ComparisonAbout APAD A Paradise Acquisition Corp. Class A Ordinary Shares
A Paradise Acquisition Corp is a blank check company.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.